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Status on Toxicogenomics Studies
The current cost to bring a drug candidate to market is estimated 
to US $1.8 billion, with an average success rate of 8% [1]. However, 
there has been a significant decrease in the development of new and 
effective drugs and one of the most important reasons for attrition was 
due to clinical side effects and toxicity. Interestingly, since the advent 
of DNA microarray technology (15 years ago), the field of toxicology 
started to discuss the great potential of genome-wide expression 
profiling for toxicity testing: the promise is that the mechanism of 
action of a chemical at the cellular level, thus the risk of chemical 
toxicity, can be identified through the transcriptional activity of cells. 
The keyword toxicogenomics was coined to identify the systematic 
approach. Moreover, at the molecular level, as the human and rodent 
genome exhibit more than 90% similarity, toxicogenomics could 
be of benefit for the extrapolation of toxic effects between species. A 
similar argument applies for extrapolating in-vivo effects from in-vitro 
experiments, although most often different parameters are measured in 
both experiments [2]. Over the last decade, a number of toxicogenomics 
studies have been performed taking advantage of the maturity of the 
microarray technology, and we consider that technology for expression 
profiling as an indicator at how the concept is gaining adoption. 
Looking on the number of references mentioning “gene expression” 
in the PubMed database, we can observe that microarray technology 
is not applied solely to toxicology but the method allows study of the 
global transcriptional changes of a given biological system in response 
to any stress perturbation. 
The “toxicogenomics” field was really investigated from 2004 
when gene expression experiments of drugs and toxicants started to be 
publicly available (Figure 1). Toxicogenomics has proven to be useful 
in toxicology [3,4]. For example in carcinogenicity, gene expression 
profiling at early time points accurately predicted non-genotoxic 
carcinogenesis and hepatocarcinogenicity [5,6]. Toxicogenomics was 
also of relevance to evaluate the potential immunotoxicity of small 
interfering RNAs (siRNAs) considered for potential therapeutic 
application [7].
Compounds inducing similar gene expression profiles to known 
model toxicants can be identified as putatively toxic based on the 
common mechanisms of response at the molecular level. Nonetheless, 
to develop such kind of profiling, access to large and consistent 
toxicogenomic repositories in conjunction with toxicological outcomes 
are required. One of the limitations is standardization and consistency 
across experimental settings, data format and metadata description 
originating from separate studies. Mostly efforts where a specific scope 
and rules governing consistency were defined, be it a disease such as 
cancer or a specific type of cancer, managed to successfully propose 
specific new knowledge out of the combined data. Within less specific 
contexts for merging microarray data co-expression of transcripts, 
giving indications about transcriptional networks in general, is mostly 
what can be achieved.
Toxicogenomics Initiatives
Among the initiatives in which large toxicogenomics reference 
data has been generated, DrugMatrix, the Toxicogenomics Projects 
Japan (TG-GATEs) and PredTox are the largest and most consistent 
databases that are now available (Table 1).
The DrugMatrix database, established by Iconix Biosciences and 
recently acquired by the National Toxicology Program, consists of 
gene expression responses in several tissues including liver, kidney, 
heart and primary hepatocytes of male Sprague-Dawley rats for over 
630 known drugs and toxicants ingested at two or more doses and 
measured at different time points in triplicate [8,9]. Histopathology, 
blood chemistry and hematology data are also included with the gene 
expression data, allowing investigating the relation between the gene 
expression differentiations and the pathology.
TG-GATEs is a recent collaboration between the National Institute 
Abstract
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of Health Sciences and 17 pharmaceutical companies in Japan [10]. 
In this initiative, male Sprague-Dawley rats have been exposed to 
131 compounds at three dose levels in single dose experiments where 
samples were collected at 3, 6, 9 and 24 hours and also repeated dosing 
experiments where samples were collected up to 29 days. Microarrays 
have been performed on liver and kidney from in vivo experiments as 
well as in vitro hepatocytes from rats and humans. The data include 
information on histopathology, hematology and clinical chemistry. 
In Europe, a collaborative project between pharmaceutical 
companies, Small and Medium Enterprises (SMEs), and universities, 
called the ‘InnoMed PredTox’ project, was performed under the EU 
Framework Program 6 [11,12]. In this project, 16 proprietary drug 
candidates that had been discontinued at certain stages of preclinical 
development due to toxicological findings in liver and/or kidney in 
2 to 4-week systemic rat studies were selected for study. Each of the 
compounds was tested in a 2-week systemic study at a low dose and a 
high dose using male Wistar rats. For all animals, clinical observations, 
serum, plasma, blood as well as liver and kidney tissues were collected 
and analyzed with transcriptomics, proteomics and metabolomics 
approaches. All the raw data are available at the BioInvestigationIndex 
(BII) site (www.ebi.ac.uk/bioinvindex/browse_studies.seam). 
An analysis of the compounds studied in these three projects shows 
that there is now publicly available data on 705 distinct compounds. 
The overlap is shown in Figure 2. Although most of the compounds 
analyzed are approved drugs by the Federal Drug Administration 
(FDA), some environmental compounds and natural products have 
also been studied. Interestingly, a major set of compounds evaluated in 
TG-GATEs has also been studied in DrugMatrix allowing comparing 
the reproducibility of the outcome from both studies. In addition, it is 
possible to integrate gene expression profiles in other tissues (heart, 
muscle, bone marrow, spleen, brain and intestine) offering a larger 
systemic view of the potential toxicity of a molecule.
Data from other microarray experiments involving compound-
treatments are also available in ArrayExpress/GEO, but a) the lack 
of common protocols will make combining and interpreting the data 
challenging, and b) the chemical indexing of these resources remains 
a challenge [13].
Data Processing and Analysis
One of the challenges in Toxicogenomics is to find subsets of 
biomolecules within large genomics data sets that have an obvious 
meaning. Widely used procedures to analyze transcriptomic data are 
Bioconductor [14], implemented in R, and DAVID (Database for 
Annotation, Visualization and Integrated Discovery), a web accessible 
tool for the interpretation of genome-scale datasets, including those 
derived from microarrays. DAVID provides exploratory visualization 
tools that promote discovery through the functional annotation of 
gene lists [15]. Since, a lot of computational biological methods have 
been developed and reported for prioritizing candidate genes [16]. 
Enrichment analyses to a gene/protein network and integration 
of pathway-level analyses have become important tools for the 
interpretation of data from transcriptomics [17,18]. For example, a 
tool like GenMAPP integrates several biological pathways relevant for 
rat and human toxicicty [19]. PINTA is another web resource for the 
prioritization of candidate genes based on the differential expression 
of their neighborhood in a genome-wide protein-protein interaction 
network [20]. Finally, a Predictive Power Estimation Algorithm 
(PPEA) has been developed to facilitate genomic biomarker discovery 
for predictive toxicity and drug responses [21]. 
The application of toxicogenomics as a predictive tool for 
chemical risk assessment has been under evaluation by the toxicology 
Figure 1: Number of papers in PubMed from 1999 to 2011 mentioning in title or abstract “toxicogenomics” in blue, “toxicology” in red and “gene expression” in green. 
The Y axis is converted into log (number of paper) for a better visualization.
Dataset Compounds Animals Doses Dosing Sampling
Drug Matrix 657 Male S-D rats* 2 daily dosing up to 5 days 6 hrs and 1,3,5 days
TG-Gates 131 Male S-D rats* 3 daily dosing up to 29 days 3, 6, 9, 24 hrs and 4,8,15,29 days 
PredTox 16 Male W Rats** 2 daily dosing up to 14 days 1,3,14 days         
* S-D: 
Sprague-Dawley
**W: Wistar rat strains
Table 1: The 3 largest toxicogenomics initiatives.
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Figure 2: Overlap of compounds analyzed in the three large toxicogenomics 
projects.
community for more than a decade following the MicroArray Quality 
Control (MAQC) guidance [22]. Recently, assessment of the level of 
inter- and intra- laboratory reproducibility between three independent 
laboratories on benzo[a]pyrene and the human hepatoma cell line 
HepG2 show that the current generation of microarray technology 
with a standard in vitro experimental design can produce robust and 
reproducible results [23]. 
eTOX Project
In 2010, a public-private partnership within the framework of the 
European Innovative Medicines Inititative (IMI), called eTOX, has 
been launched to gather relevant toxicity data from public sources (e.g. 
scientific literatures and non-proprietary databases) and to develop 
innovative strategies for the in silico prediction of the in vivo toxicities 
of drugs.
The final product should be implemented into a database with 
integrated and customizable software tools.  More information is 
available at this link: http://www.etoxproject.eu/.
An interesting aspect of this project is the participation of 13 
pharmaceutical companies who agreed to provide high quality in vivo 
toxicity data for a pull of compounds, which can be shared among the 
consortium. The primary focus of their data collections is the systemic 
toxicity studies (1-4 week repeated dose studies in rats, dogs and other 
non-rodents). The data collection is intended to be extended to longer 
studies, as well as to pharmacokinetic/toxicokinetic studies, in vivo 
safety pharmacology or gene expression data sets, during the course 
of the five years project. Currently, around 2000 reports are planned to 
be released to the consortium and more than 100 reports processed by 
contract research organizations (CROs) have been completed.
In parallel to data collection, strategies to improve the toxicity 
prediction are also currently investigated under eTOX. Development 
and application of large-scale Quantitative Structure-Activity 
Relationship (QSAR) models for the prediction of toxicity outcomes 
and off-target pharmacology such as the hERG K+ channel, metabolites 
enzymes and drug transporters and pure chemistry-related toxicology 
(e.g. cationic amphiphilic drug and phospholipidosis, mutagenicity) 
will be performed and analyzed. Development of multi-scales and 
multi-levels modeling techniques to outperform the possible complex 
relationships existing between biomolecular processes and resulting 
toxicity outcomes will be explored.
The last objective is to understand the molecular mechanisms 
associated to in vivo toxicicty. To reach this goal incorporation 
of omics data and cross-omics mapping is intended. As a start, it is 
planned, to integrate the large toxicogenomics datasets, previously 
mentioned, in a curated database accessible to the public and then to 
analyze in-vivo (and in-vitro) toxicological profiles. To our knowledge, 
comparison of the data studied in TG-GATEs and DrugMatrix has 
not been yet performed and an in-depth comparison will be one of 
the aims in the eTOX project to evaluate the reproducibility of the 
outcome. Taking advantage of the recent advances in this area, we 
will assess the transcriptomics data with the integration of biological 
pathways and gene enrichment and we will try to address the variations 
of the toxicological events observed in different species and evaluate 
the translation of toxicity findings across species. One of the challenges 
will be to predict the potential in vivo toxicological profile of a drug 
and to capture the underlying mechanistic events associated with 
toxicity. Within the eTOX consortium we will explore the possibility of 
integrating toxicogenomics data analysis with the more classical QSAR 
modeling. Recently, it was reported that models from toxicogenomics 
data on non-genotoxic hepatocarcinogenicity outperformed QSAR 
model on the same set of compounds [24]. In addition, Low Y. et al. 
showed that hybrid models combining both chemical descriptors and 
gene expression profiles could be useful for the interpretation of drug-
induced hepatotoxicity [25]. Therefore, in parallel to the QSAR models 
that will be developed by the eTOX project for several toxicity endpoints 
(phospholipidosis, hepatotoxicity, nephrotoxicity, carcinogenicity, 
mutagenicity), toxicogenomics models will be investigated with the 
same set of available data and combined when possible into a hybrid 
model. A workflow is depicted in Figure 3. Depending on the biological 
information associated with a compound, it should be possible to 
predict the potential toxicity (or non toxicity) in different ways.  For 
example, if a transcriptomic experiment has been performed on a 
chemical without toxicological information, the potential toxicity can 
be suggested on the basis of similar gene expression profiles to those 
of known toxicants. Additionally, prediction can be made through 
QSAR approaches using molecular descriptors.  Using QSAR models 
in combination with the gene expression profiles will result in hybrid 
models more predictive and with better interpretation than simple 
QSAR models. 
Ultimately, based on structural similarity or structural alerts, 
mechanism of action can be proposed, although the accuracy of such 
procedure is still not optimal. It is expected with the integration of 
unpublished data from pharmaceutical companies to move towards 
a predictive and reliable modeling of the complex relationships 
existing between in vivo observations of the toxicity and safety of drug 
candidates. 
Perspectives
The combination of transcriptomics, proteomics and metabolomics 
with conventional toxicology approaches has been shown to be useful 
for mechanistic investigations and the identification of putative 
biomarkers [8]. In addition, with the advance in Next Generation 
Sequencing (NGS) technologies, it is now possible to decode an entire 
human transcriptome, making RNA sequencing a feasible way of 
obtaining global transcriptome information with reduced time and 
cost [26]. NGS will significantly accelerate genomic research and 
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Figure 2: A workflow for the development of toxicogenomics models and their integration with QSAR models.
discovery with a potential contribution on personalized medicine [27]. 
By providing the means to sequence up to few human genomes in a 
single run with an high-end sequencer such as currently an HiSeq for 
Illumina or a SOLiD 5500 from Life Technologies, recent machines 
have opened the door to the systematic exploration of mutations 
and epigenetic patterns. Recently a comparison of the NGS and 
microarray technologies on toxicogenomics data was performed on 
aristolochic acid (a nephrotoxic compound) [28]. Although RNA-
seq was more sensitive in detecting genes with low expression levels, 
similar gene expression patterns were observed for both platforms 
and encouragingly the biological interpretation was largely consistent 
between the RNA-Seq and microarray data. However, it is too early to 
estimate if such data will be available in large enough quantities to be 
of value to integrate in the eTOX project. In the context of personalized 
medicine we are only at the beginning and the toxicological component 
will play an obvious and important role: as much as the efficacy of 
compounds will vary across individuals according to specific genetic 
backgrounds the toxicity and side effects of compounds will also vary 
according to genetics. The best treatment for a given individual will 
be the drug that offers the best efficacy for the lowest amount of side 
effects.
Overall, integrating toxicogenomics in combination with other 
“omics” and other sequencing of mammalian genomes should open 
the development of new approaches for the understanding of toxicity 
as it might be affected by genetic variability. 
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